Tenex (Guanfacine) for Pediatric ADHD
Guanfacine extended-release is FDA-approved as a second-line nonstimulant medication for ADHD in children aged 6-17 years, either as monotherapy when stimulants are unsuitable or as adjunctive therapy with stimulants. 1
Indications
- Primary indication: Treatment of ADHD in children and adolescents aged 6-17 years 1, 2
- First-line use: Only when stimulants are not suitable, not tolerated, or have been shown ineffective 2
- Adjunctive therapy: FDA-approved for combination with stimulants when monotherapy provides inadequate symptom control 1
- Not recommended: For preschool children (ages 4-5 years) due to insufficient rigorous study in this population 1
Dosing Recommendations
Weight-based dosing with once-daily administration 2:
- Starting approach: 0.05-0.12 mg/kg/day, with 0.1 mg/kg as a rule of thumb 2
- Children 6-12 years: 1-4 mg/day 2, 3
- Adolescents 13-17 years: 1-7 mg/day 2, 4
- Available tablet strengths: 1,2,3, and 4 mg 2
- Titration: Gradual dose optimization over several weeks, as therapeutic effects typically emerge after 2-4 weeks of treatment 2
Monitoring Requirements
Pre-Treatment Assessment
Obtain comprehensive cardiac history before initiating therapy 1:
- Personal history of cardiac symptoms
- Family history of sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, and long QT syndrome
- If risk factors present: Perform ECG and consider pediatric cardiology referral if ECG abnormal 1
Ongoing Monitoring
Monitor cardiovascular parameters regularly 1, 2:
- Heart rate: Expect decreases; bradycardia is a known adverse effect 1, 2
- Blood pressure: Expect decreases; hypotension may occur 1, 2
- Both parameters typically decrease with dose escalation and return toward baseline during maintenance 5
Adverse Effects Profile
Most common treatment-emergent adverse events (>15% incidence) 1, 6, 3:
- Somnolence (38.6%) - typically emerges within first 2 weeks and often resolves 6, 5
- Headache (20.5%) 6
- Fatigue (15.2%) 6
- Additional effects: dry mouth, dizziness, irritability, abdominal pain 1
Approximately 80% of patients experience at least one adverse event, with most being mild-to-moderate in severity 6, 3
Critical Safety Considerations
Discontinuation Protocol
Never abruptly discontinue guanfacine 1:
- Rebound hypertension has been observed with sudden cessation 1
- Required approach: Taper the medication gradually 1
Timing of Administration
Administer in the evening when possible 2:
- Mitigates somnolence and sedation, which are frequent adverse effects 2
- Somnolence typically emerges early in treatment and generally resolves by study end 5
Efficacy Expectations
Effect size and timeline 2, 6:
- Medium-range effect sizes compared to placebo, smaller than stimulants 2
- Treatment response (CGI-I ≤2): 58.5-63.6% with guanfacine vs 29.4-39.7% with placebo 6
- Onset of action: 2-4 weeks until effects are observed 2
- Provides "around-the-clock" symptom coverage unlike short-acting stimulants 2
Special Clinical Scenarios
Consider guanfacine as preferred option when 2:
- Comorbid sleep disorders exist
- Comorbid substance use disorders are present
- Comorbid disruptive behavior disorders or tic/Tourette's disorder
- Stimulant effectiveness or tolerability is of concern
Combination therapy: Extended-release guanfacine has FDA approval and evidence supporting adjunctive use with stimulants when monotherapy is insufficient 1